                               SEQUENCE LISTING

<110> NAUTILUS BIOTECHNOLOGY, INC.
 
<120> AFFINITY REAGENTS HAVING ENHANCED BINDING AND DETECTION 
      CHARACTERISTICS

<130> G8066

<140> PCT/US2021/058851
<141> 2021-11-10

<150> 63/227,080
<151> 2021-07-29

<150> 63/132,170
<151> 2020-12-30

<150> 63/112,607
<151> 2020-11-11

<160> 17    

<170> PatentIn version 3.5

<210> 1
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 1
Ala Ala Ala Ala Ala 
1               5   


<210> 2
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 2
Ala Ala Ala Ala Cys 
1               5   


<210> 3
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 3
Cys Ala Ala Ala Ala 
1               5   


<210> 4
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 4
Cys Ala Ala Ala Cys 
1               5   


<210> 5
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 5
Cys Ala Ala Ala Asp 
1               5   


<210> 6
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 6
Arg Gly Asp Ser 
1               


<210> 7
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 7
Arg Gly Glu Ser 
1               


<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"

<400> 8
atctcgtatg ccgtcttctg cttg                                              24


<210> 9
<211> 133
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polynucleotide"

<400> 9
caagcagaag acggcatacg agatcatgct tccccaggga gatggtttgc cggtgggcag       60

gtttagggtc tgctcgggat tgcggaggaa catgcgtcgc aaacgtgtag atctcggtgg      120

tcgccgtatc att                                                         133


<210> 10
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 10
Thr Ala Ala Ala Leu 
1               5   


<210> 11
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 11
Tyr Ala Ala Ala Ser 
1               5   


<210> 12
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 12
Met Ala Ala Ala Thr 
1               5   


<210> 13
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 13
Ala Ala Ala Ala Asp 
1               5   


<210> 14
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 14
Tyr Ala Ala Ala Ala 
1               5   


<210> 15
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 15
Tyr Ala Ala Ala Cys 
1               5   


<210> 16
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 16
Tyr Ala Ala Ala Asp 
1               5   


<210> 17
<211> 5
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 
      Target peptide sequence"

<400> 17
Tyr Ala Ala Ala Tyr 
1               5   


